摘要
目的:观察托伐普坦治疗慢性心力衰竭(CHF)患者低钠血症的临床疗效,并对其安全性进行评价。方法:将16例CHF伴低钠血症患者随机分为治疗组(常规治疗+托伐普坦)8例和对照组(常规治疗)8例。采用双盲对照法,比较2组患者治疗8及24h的血钠、尿量及体质量;治疗8d后采用明尼苏达州心衰生活质量问卷(MLHFQ)进行评分并观察用药期间的不良反应。结果:治疗组患者用药8及24h后血钠水平明显高于对照组(P<0.01);治疗组患者治疗24h后尿量较治疗前有明显增加(P<0.05),但与对照组比较差异无统计学意义(P>0.05);2组治疗8d后MLHFQ评分较治疗前有明显改善(P<0.01),治疗组较对照组改善更明显(P<0.05);2组患者均未出现不良事件,治疗组有1例出现口干不良反应。结论:应用托伐普坦治疗CHF患者低钠血症疗效确切,可改善患者生活质量,安全性及耐受性良好。
Objective To observe the clinical efficacy of tolvaptan in treatment of hyponatremia in patients with chronic heart failure（CHF）and to evaluate its efficacy and safety.Methods 16 patients with CHF and hyponatremia were randomly divided into therapy group（conventional treatment＋tolvaptan,8cases）and control group（conventional treatment,8cases）.All the patients were evaluated by observing the serum sodium,serum sodium,urine volume and body weight 8and 24hafter treatment with double-blind control method,and Minnesota Living with Heart Failure Questionnaire（MLHFQ）was performed 8dafter treatment,and the adverse reactions were observed.Results The levels of serum sodium of the patients in therapy group 8and 24hafter treatment were significantly higher than those in control group（P0.01）.The urine volume of the patients in therapy group 24hafter treatment was increased compared with before treatment（P0.05）,but there was no significant difference between therapy group and control group（P0.05）.The MLHFQ of the patients in two groups 8d after treatment were significantly improved compared with before treatment（P0.01）,the improvement in therapy group was more significant compared with control group（P0.05）.There were no adverse events,and only 1case of dry mouth was found in therapy group.Conclusion The efficacy of tolvaptan in treatment of the patients with CHF and hyponatremia is better,and it can improve their qualities of life with good safety and tolerability.
出处
《吉林大学学报（医学版）》
CAS
CSCD
北大核心
2013年第5期995-998,共4页
Journal of Jilin University：Medicine Edition
基金
吉林省科技厅自然科学基金资助课题(201115094)
